367 related articles for article (PubMed ID: 25607903)
1. Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentation.
Wanner M; Houston N; Javorsky E; Yuan M; Alora-Palli M; Kimball AB
J Drugs Dermatol; 2015 Jan; 14(1):13-8. PubMed ID: 25607903
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of hydroquinone-free skin-lightening cream for photoaging.
Dreher F; Draelos ZD; Gold MH; Goldman MP; Fabi SG; Puissegur Lupo ML
J Cosmet Dermatol; 2013 Mar; 12(1):12-7. PubMed ID: 23438137
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the benefits of a topical treatment in the improvement of photodamaged hands with age spots, freckles, and/or discolorations.
Gold MH; Gallagher C
J Drugs Dermatol; 2013 Dec; 12(12):1468-72. PubMed ID: 24301250
[TBL] [Abstract][Full Text] [Related]
5. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
Serra M; Bohnert K; Narda M; Granger C; Sadick N
J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of two commercial hyperpigmentation kits in the treatment of facial hyperpigmentation and photo-aging.
Fabi S; Massaki N; Goldman MP
J Drugs Dermatol; 2012 Aug; 11(8):964-8. PubMed ID: 22859242
[TBL] [Abstract][Full Text] [Related]
7. Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study.
Lowe N; Gifford M; Tanghetti E; Poulin Y; Goldman M; Tse Y; Yamauchi P; Rosenzweig H; Kang S
J Cosmet Laser Ther; 2004 Jun; 6(2):79-85. PubMed ID: 15203997
[TBL] [Abstract][Full Text] [Related]
8. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies.
Fleischer AB; Schwartzel EH; Colby SI; Altman DJ
J Am Acad Dermatol; 2000 Mar; 42(3):459-67. PubMed ID: 10688717
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of β-arbutin, in selected skin hyperpigmentations.
Morag M; Nawrot J; Siatkowski I; Adamski Z; Fedorowicz T; Dawid-Pac R; Urbanska M; Nowak G
J Cosmet Dermatol; 2015 Sep; 14(3):185-90. PubMed ID: 26119285
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
Monheit GD; Dreher F
J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908
[TBL] [Abstract][Full Text] [Related]
12. Topical tretinoin for treatment of photodamaged skin. A multicenter study.
Weinstein GD; Nigra TP; Pochi PE; Savin RC; Allan A; Benik K; Jeffes E; Lufrano L; Thorne EG
Arch Dermatol; 1991 May; 127(5):659-65. PubMed ID: 2024983
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
Fabi SG; Goldman MP
J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
[TBL] [Abstract][Full Text] [Related]
14. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial.
Griffiths CE; Finkel LJ; Ditre CM; Hamilton TA; Ellis CN; Voorhees JJ
Br J Dermatol; 1993 Oct; 129(4):415-21. PubMed ID: 8217756
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation.
Makino ET; Mehta RC; Banga A; Jain P; Sigler ML; Sonti S
J Drugs Dermatol; 2013 Mar; 12(3):s16-20. PubMed ID: 23545928
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, controlled comparative trial of the anti-aging properties of non-prescription tri-retinol 1.1% vs. prescription tretinoin 0.025%.
Ho ET; Trookman NS; Sperber BR; Rizer RL; Spindler R; Sonti S; Gotz V; Mehta R
J Drugs Dermatol; 2012 Jan; 11(1):64-9. PubMed ID: 22206079
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
Bruce S
J Drugs Dermatol; 2013 Mar; 12(3):S27-31. PubMed ID: 23545930
[TBL] [Abstract][Full Text] [Related]
19. Novel approach to the treatment of hyperpigmented photodamaged skin: 4% hydroquinone/0.3% retinol versus tretinoin 0.05% emollient cream.
Draelos ZD
Dermatol Surg; 2005 Jul; 31(7 Pt 2):799-804. PubMed ID: 16029670
[TBL] [Abstract][Full Text] [Related]
20. Topical tretinoin (retinoic acid) treatment of hyperpigmented lesions associated with photoaging in Chinese and Japanese patients: a vehicle-controlled trial.
Griffiths CE; Goldfarb MT; Finkel LJ; Roulia V; Bonawitz M; Hamilton TA; Ellis CN; Voorhees JJ
J Am Acad Dermatol; 1994 Jan; 30(1):76-84. PubMed ID: 8277035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
